Brokerages Anticipate PTC Therapeutics, Inc. (NASDAQ:PTCT) to Post -$0.47 EPS

Brokerages expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings per share of ($0.47) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for PTC Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.78). PTC Therapeutics posted earnings of ($0.46) per share in the same quarter last year, which indicates a negative year over year growth rate of 2.2%. The business is expected to issue its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that PTC Therapeutics will report full-year earnings of ($3.74) per share for the current year, with EPS estimates ranging from ($3.87) to ($3.61). For the next year, analysts expect that the firm will post earnings of ($1.49) per share, with EPS estimates ranging from ($1.69) to ($1.36). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow PTC Therapeutics.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.15). The business had revenue of $71.40 million during the quarter, compared to analysts’ expectations of $72.03 million. PTC Therapeutics had a negative net margin of 74.86% and a negative return on equity of 31.92%. The firm’s quarterly revenue was up 33.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.06) EPS.

Several equities analysts have recently weighed in on PTCT shares. William Blair reaffirmed a “buy” rating on shares of PTC Therapeutics in a research note on Tuesday, November 26th. Credit Suisse Group reaffirmed a “buy” rating and issued a $54.00 price objective on shares of PTC Therapeutics in a research note on Thursday, October 31st. ValuEngine lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 4th. SunTrust Banks started coverage on PTC Therapeutics in a research note on Tuesday, November 12th. They issued a “buy” rating and a $78.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $58.00 price objective on shares of PTC Therapeutics in a research note on Thursday, December 5th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $57.00.

In related news, CAO Christine Marie Utter sold 13,750 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $50.02, for a total transaction of $687,775.00. Following the transaction, the chief accounting officer now directly owns 5,224 shares of the company’s stock, valued at approximately $261,304.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stuart Walter Peltz sold 1,797 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $48.17, for a total value of $86,561.49. Following the transaction, the chief executive officer now directly owns 23,085 shares in the company, valued at $1,112,004.45. The disclosure for this sale can be found here. Insiders have sold a total of 38,924 shares of company stock worth $1,928,710 over the last three months. 7.00% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in PTCT. Meeder Asset Management Inc. increased its holdings in PTC Therapeutics by 2,347.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 1,738 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,667 shares during the last quarter. Exane Derivatives purchased a new stake in PTC Therapeutics during the 4th quarter worth approximately $100,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in PTC Therapeutics by 15.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,596 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 474 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in PTC Therapeutics during the 3rd quarter worth approximately $130,000. Finally, Nomura Holdings Inc. purchased a new stake in PTC Therapeutics during the 3rd quarter worth approximately $212,000. 99.30% of the stock is currently owned by hedge funds and other institutional investors.

PTCT opened at $51.92 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.40 and a quick ratio of 4.30. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -12.79 and a beta of 1.91. The business has a 50-day moving average of $49.86 and a two-hundred day moving average of $44.02. PTC Therapeutics has a 12 month low of $27.53 and a 12 month high of $54.37.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Read More: How are dividend achievers different from dividend aristocrats?

Get a free copy of the Zacks research report on PTC Therapeutics (PTCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.